AT426408T - Pharmaceutical compositions containing botulinum toxin and human serum albumin - Google Patents

Pharmaceutical compositions containing botulinum toxin and human serum albumin

Info

Publication number
AT426408T
AT426408T AT03814518T AT03814518T AT426408T AT 426408 T AT426408 T AT 426408T AT 03814518 T AT03814518 T AT 03814518T AT 03814518 T AT03814518 T AT 03814518T AT 426408 T AT426408 T AT 426408T
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
serum albumin
compositions containing
human serum
botulinum toxin
Prior art date
Application number
AT03814518T
Other languages
German (de)
Inventor
Gary Borodic
Original Assignee
Botulinum Toxin Res Ass Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US43590102P priority Critical
Application filed by Botulinum Toxin Res Ass Inc filed Critical Botulinum Toxin Res Ass Inc
Publication of AT426408T publication Critical patent/AT426408T/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32713047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT426408(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/468The waterborne disease being caused by a bacteria
    • Y02A50/469The waterborne disease being caused by a bacteria the bacteria being clostridium botulinum, i.e. Botulism
AT03814518T 2002-12-20 2003-12-22 Pharmaceutical compositions containing botulinum toxin and human serum albumin AT426408T (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US43590102P true 2002-12-20 2002-12-20

Publications (1)

Publication Number Publication Date
AT426408T true AT426408T (en) 2009-04-15

Family

ID=32713047

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03814518T AT426408T (en) 2002-12-20 2003-12-22 Pharmaceutical compositions containing botulinum toxin and human serum albumin

Country Status (17)

Country Link
US (2) US7491403B2 (en)
EP (1) EP1594523B1 (en)
JP (1) JP2006519761A (en)
KR (1) KR20050094817A (en)
CN (1) CN100525831C (en)
AT (1) AT426408T (en)
AU (2) AU2003300666A1 (en)
BR (1) BR0316871A (en)
CA (1) CA2510058C (en)
CR (1) CR9813A (en)
DE (1) DE60326887D1 (en)
IL (1) IL168745D0 (en)
MX (1) MXPA05006690A (en)
NO (1) NO20053424A (en)
NZ (1) NZ540425A (en)
WO (1) WO2004060384A2 (en)
ZA (1) ZA200504982B (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US7459164B2 (en) * 2002-05-28 2008-12-02 Botulinum Toxin Research Associates, Inc. Composition for therapeutic and cosmetic botulinum toxin
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
AT426408T (en) * 2002-12-20 2009-04-15 Botulinum Toxin Res Ass Inc Pharmaceutical compositions containing botulinum toxin and human serum albumin
WO2004078200A1 (en) * 2003-03-06 2004-09-16 Botulinum Toxin Research Associates, Inc. Selection of patients with increased responsiveness to botulinum toxin
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
DE602005018162D1 (en) * 2004-01-05 2010-01-21 Botulinum Toxin Res Ass Inc A method for use of botulinum toxin for treatment of hypervolaemic lippendeformität (lip ectropion)
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
KR100852824B1 (en) * 2004-07-26 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 Therapeutic composition with a botulinum neurotoxin
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
WO2006073410A1 (en) * 2005-01-03 2006-07-13 Botulinum Toxin Research Associates, Inc. Compositions, methods and devices for preparing less painful botulinum toxin formulations
US7727537B2 (en) 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
US7838011B2 (en) 2005-02-14 2010-11-23 Pankaj Modi Stabilized protein compositions for topical administration and methods of making same
WO2008010788A2 (en) 2005-07-18 2008-01-24 University Of Massachusetts Lowell Compositions and methods for making and using nanoemulsions
US9511210B2 (en) 2006-05-19 2016-12-06 The Foundry, Llc Apparatus for toxin delivery to the nasal cavity
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
WO2007014003A2 (en) 2005-07-22 2007-02-01 The Foundry Inc. Systems and methods for delivery of a therapeutic agent
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
AU2013202882B2 (en) * 2005-08-01 2015-11-19 Allergan, Inc Improved botulinum toxin compositions
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
PT1959994T (en) 2005-12-01 2017-11-30 Univ Of Massachusetts Lowell Botulinum nanoemulsions
US20080063732A1 (en) * 2006-07-31 2008-03-13 Hantash Basil M Method of increasing the efficacy of neurotoxin
BRPI0719732A2 (en) 2006-12-01 2017-05-16 Anterios Inc peptide nanoparticles and uses for the same
JP2010528981A (en) 2006-12-01 2010-08-26 アンテリオス, インコーポレイテッド Amphiphilic entity nanoparticles
KR20150028856A (en) 2007-05-31 2015-03-16 안테리오스, 인코퍼레이티드 Nucleic acid nanoparticles and uses therefor
KR100882817B1 (en) * 2007-07-20 2009-02-10 사회복지법인 삼성생명공익재단 Pharmaceutical composition for improving engraftment of adipose cell comprising botulinum toxin as an active ingredient
US9161970B2 (en) 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
US9044477B2 (en) * 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
CN102014779B (en) 2008-05-09 2014-10-22 赫莱拉公司 A system, components and methods for treating bronchial tree
EP2364168A1 (en) * 2008-12-04 2011-09-14 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
ES2538835T3 (en) * 2009-01-07 2015-06-24 Robert John Petrella Treatment of soft tissue injuries using hyaluronic acid and botulinum toxin
CA2766649C (en) 2009-06-24 2016-08-23 Charles N.S. Soparkar Zinc supplementation to increase responsiveness to metalloprotease therapy
CA2779135C (en) 2009-10-27 2018-09-04 Innovative Pulmonary Solutions, Inc. Delivery devices with coolable energy emitting assemblies
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
AU2010319477A1 (en) 2009-11-11 2012-05-24 Holaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
ES2634669T3 (en) 2011-02-08 2017-09-28 Halozyme, Inc. Lipid composition and formulation of a hyaluronan degrading enzyme and use thereof for the treatment of benign prostatic hyperplasia
EP2849781B1 (en) 2012-03-12 2017-09-13 William J. Binder Treatment of migraine headaches with presynaptic neurotoxin
US8722060B2 (en) * 2012-05-23 2014-05-13 William J. Binder Method of treating vertigo
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
WO2017188618A1 (en) * 2016-04-26 2017-11-02 Korea Prime Pharm Co., Ltd. A novel composition comprising botulinum toxin
KR101636846B1 (en) * 2016-06-08 2016-07-07 (주)넥스젠바이오텍 Botulium toxin-human epidermal growth factor fusion protein with increased skin cell proliferation and antioxidative effect and cosmetic composition for improving wrinkle and promoting skin reproduction comprising the same as effective component

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2160312B (en) 1984-04-13 1987-09-16 South African Inventions Adjuvant for immunisation
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US5069936A (en) * 1987-06-25 1991-12-03 Yen Richard C K Manufacturing protein microspheres
US5053005A (en) * 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
US5034461A (en) * 1989-06-07 1991-07-23 Bausch & Lomb Incorporated Novel prepolymers useful in biomedical devices
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
JP3510886B2 (en) * 1992-06-23 2004-03-29 ボツリヌム トキシン リサーチ アソシエイト インコーポレイテッド Pharmaceutical compositions containing botulinum b complex
JPH06192118A (en) * 1992-09-28 1994-07-12 Wisconsin Alumni Res Found Botulinum toxin-containing pharmaceutical composition for treating abnormally-hypersensitive muscular movement disorder and its preparation
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US5401452A (en) * 1993-07-26 1995-03-28 Environmental Protection Polymers, Inc. Methods for encapsulating waste and products thereof
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US20040126396A1 (en) * 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
AU710504B2 (en) * 1994-03-15 1999-09-23 Brown University Research Foundation Polymeric gene delivery system
EP0760681B1 (en) * 1994-05-31 1999-09-01 Allergan, Inc Modification of clostridial toxins for use as transport proteins
US5583162A (en) * 1994-06-06 1996-12-10 Biopore Corporation Polymeric microbeads and method of preparation
WO1996005222A1 (en) * 1994-08-08 1996-02-22 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
DE69627963T2 (en) * 1995-06-06 2004-03-04 Allergan, Inc., Irvine Improved compositions and methods for Chemodenervation with neurotoxins
AU4746096A (en) 1995-06-06 1996-12-24 Wisconsin Alumni Research Foundation Analogs of botulinum toxin and pharmaceutical compositions o f botulinum toxin
US5939070A (en) * 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
US5965699A (en) * 1996-11-06 1999-10-12 The United States Of America As Represented By The Secretary Of The Army Assay for the proteolytic activity of serotype a from clostridium botulinum
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6051239A (en) * 1997-10-20 2000-04-18 Thomas Jefferson University Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
US6214602B1 (en) * 1998-08-28 2001-04-10 Promega Corporation Host cells for expression of clostridial toxins and proteins
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
MXPA01004254A (en) * 1998-10-27 2002-04-24 Mayo Foundation Methods for enhancing wound healing.
US6545126B1 (en) * 1999-03-18 2003-04-08 Wisconsin Alumni Research Foundation Chimeric toxins
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6429189B1 (en) * 1999-12-10 2002-08-06 Botulinum Toxin Research Associates, Inc. Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
AT519494T (en) * 2000-02-08 2011-08-15 Allergan Inc Pharmaceutical compositions containing botulinum toxin
US20030138460A1 (en) * 2000-02-08 2003-07-24 Allergan, Inc Methods of treating animals with botulinum toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20030086899A1 (en) * 2000-03-14 2003-05-08 Jafari Masoud R. Chondroitin sulfate containing viscoelastics for use in treating joints
US6579847B1 (en) * 2000-05-01 2003-06-17 Imarx Therapeutics Inc. Method and apparatus for vascular neuromuscular blockade
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US7255865B2 (en) * 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
ITUD20010002A1 (en) * 2001-01-05 2002-07-05 Univ Degli Studi Udine Use of botulinum toxin for the joint solution diseases, particularly osteoarthritis, and epicondylitis of the pathological
WO2003015698A2 (en) * 2001-08-13 2003-02-27 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
MXPA01011542A (en) * 2001-11-13 2003-05-22 Alcon Inc Regeneration of articular cartilage damaged by osteoarthritis i and ii, by means of intra-articular application of sodium hyaluronate and chondroitin sulphate in a gel carrier.
US7140371B2 (en) * 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US7459164B2 (en) * 2002-05-28 2008-12-02 Botulinum Toxin Research Associates, Inc. Composition for therapeutic and cosmetic botulinum toxin
AT426408T (en) * 2002-12-20 2009-04-15 Botulinum Toxin Res Ass Inc Pharmaceutical compositions containing botulinum toxin and human serum albumin
CA2518157C (en) * 2003-03-06 2018-09-04 Botulinum Toxin Research Associates, Inc. Treatment of sinusitis related chronic facial pain and headache with botulinum toxin
MXPA05009424A (en) * 2003-03-06 2006-02-10 Botulinum Toxin Res Ass Inc Treatment of chronic chalazion and hordeolum with botulinum toxin.
DE602005018162D1 (en) * 2004-01-05 2010-01-21 Botulinum Toxin Res Ass Inc A method for use of botulinum toxin for treatment of hypervolaemic lippendeformität (lip ectropion)
WO2006073410A1 (en) * 2005-01-03 2006-07-13 Botulinum Toxin Research Associates, Inc. Compositions, methods and devices for preparing less painful botulinum toxin formulations
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions

Also Published As

Publication number Publication date
JP2006519761A (en) 2006-08-31
US8241640B2 (en) 2012-08-14
CN1729011A (en) 2006-02-01
CN100525831C (en) 2009-08-12
EP1594523B1 (en) 2009-03-25
DE60326887D1 (en) 2009-05-07
CA2510058A1 (en) 2004-07-22
CR9813A (en) 2008-07-29
US20110293663A1 (en) 2011-12-01
AU2010202062A1 (en) 2010-06-10
ZA200504982B (en) 2007-05-30
EP1594523A2 (en) 2005-11-16
NO20053424D0 (en) 2005-07-14
BR0316871A (en) 2005-10-18
NO20053424A (en) 2005-09-16
AU2003300666A1 (en) 2004-07-29
US7491403B2 (en) 2009-02-17
WO2004060384A3 (en) 2004-10-07
WO2004060384A2 (en) 2004-07-22
NZ540425A (en) 2009-03-31
KR20050094817A (en) 2005-09-28
CA2510058C (en) 2010-03-16
IL168745D0 (en) 2011-12-01
MXPA05006690A (en) 2006-02-17
US20040151741A1 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
DK1329456T3 (en) The glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
DE60044213D1 (en) Stabilized liquid pharmaceutical composition comprising TFPI
DE60019722D1 (en) Pharmaceutical compositions for discomfort rundown
DE69834204D1 (en) Cyclic amino acids and their derivatives as drug
DE60027458D1 (en) Microchip drug administration systems and manufacturing processes
AT297723T (en) A pharmaceutical composition comprising a 5-aminolevulinic acid-ester as a photochemotherapeutic agent and a mucoadhesive
DE60236183D1 (en) Display device and its control system
BRPI9707379B8 (en) Pharmaceutical compositions comprising recombinant human antibody genetically engineered, recombinant and genetically engineered human antibody.
DK1414471T3 (en) Therapeutic agents comprising pro-apoptotic proteins
DE60138768D1 (en) Glucopyranosylpyrazolderivate and their use in medicinal products
NO20035645D0 (en) Enhanced drug delivery in transdermal systems
DE60121992D1 (en) Composition for administration and coating medical devices
DE69520882D1 (en) Pharmaceutical composition comprising amoxycillin and kaliumclavunalat
AT264750T (en) Composition and films thereof
AT279961T (en) New pharmaceutical composition
AT410964T (en) Snaps in disc and arrangements thereof
DE60204058D1 (en) Network-forming and pectin-containing preparation
DE60237449D1 (en) Ammensetzungen and related uses relationship
AT509616T (en) The topical pharmaceutical and / or dosage systems cosmetische
DE69717294D1 (en) Quinazoline derivatives and pharmaceutical compositions containing them
RU2003127750A (en) 4-fluoro-n-indan-2-yl-benzamide and its use as pharmaceutical agent
DE60231868D1 (en) Folate mimetics and their conjugates folatrezeptorbindende
EE04144B1 (en) The pharmaceutical composition and the use thereof
DE69522225D1 (en) Rapamycinamidinocarbamate and pharmaceutical compositions containing them
BR0110843B1 (en) Composition and transdermal drug delivery system

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties